Articles related to LUNG CANCER

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

The recent phase 3 trial has demonstrated the potential of amivantamab as a first-line treatment option for patients with advanced NSCLC with EGFR exon 20 insertions. The combination of amivantamab and chemotherapy significantly improved progression-free survival compared to chemotherapy alone.

The study underscores the potential of perioperative durvalumab in combination with neoadjuvant chemotherapy to significantly improve event-free survival and pathological complete response in patients with resectable NSCLC.

The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.

This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.

Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.